Osteoarthritis affects millions, yet current medical options remain limited to symptom management or joint replacement. A team at University of Utah Health is working to change this. They recently combined genetic research from local families with AI to identify potential new drugs for the condition.
Researchers focused on the WNK2 gene, which previous studies linked to the progression of hereditary forms of osteoarthritis. By using AI to predict the protein structure of WNK2, the team simulated interactions with half a million chemical compounds. This process allowed them to narrow the search down to six promising candidates in just a few weeks.
One specific compound, M04, showed positive results in lab-based models using human cartilage cells. The drug reduced genes associated with inflammation and increased expression of genes that promote cell health. While this research provides a clear path forward, the team notes that further studies are required to determine safety and efficacy in living organisms before any clinical use.
The findings, published in ACS Omega, serve as an initial step toward developing treatments that address the underlying disease process rather than just the pain. Future work will involve collaborating with the University of Utah Therapeutics Accelerator Hub to develop improved versions of the drug and testing them in animal models.